However, more investigations are needed to have a more controlled and homogenous release of fulvestrant or other drugs throughout the entire mammary gland since a much more pronounced decrease in the Ki-67 proliferation marker was measured in tumor areas adjacent to the tubing implant [96]. This evidence concerns the gene MKI67 and neoplasm.